ArticleNature2025
Programs, origins and immunomodulatory functions of myeloid cells in glioma.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 1 synthesis or guideline pooled it.
- cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes.Journal of neuro-oncology · 2026Pooled it
- Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial.Nature medicine · 2026Trial
- Article
- Single-cell transcriptome-guided biomimetic magnetothermal hydrogel microspheres for multimodal eradication of residual glioblastoma.Bioactive materials · 2026Article
- AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer.iScience · 2026Review
- Neuro-immune interactions in tumors, immune-related disorders, and infections.Signal transduction and targeted therapy · 2026Review
- MAPK-driven glioma progression and reprogramming of the tumor-associated immune response.Neuro-oncology · 2026Article
- Mitochondrial transfer-driven immune evasion in the tumor microenvironment.International immunology · 2026Review
- Convection-enhanced delivery of dexamethasone in glioma models suppresses myeloid inflammation while avoiding systemic toxicities.The Journal of clinical investigation · 2026Article
- Integrated multi-omics identifies lineage-dependent myeloid cells recruitment and the APP-CD74 axis as an immunoregulatory target in pediatric high-grade glioma.Acta neuropathologica · 2026Article
- Glioma microenvironment: Cellular crosstalk, immunosuppression, and novel therapeutic perspectives.Chinese medical journal · 2026Review
- Microenvironment-derived acetylated amino acids promote glioblastoma treatment resistance.Research square · 2026Article
- Spatial analysis reveals the evolving organization of IDH-mutant glioma.Cancer cell · 2026Article
- TREM2 in glioma: Reprogramming the immune microenvironment from mechanistic understanding to clinical translation (Review).Molecular medicine reports · 2026Review
- The Invasive Margin of Glioblastoma as a Molecular Ecosystem: Spatial Heterogeneity, Tumor-Host Interactions, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.Cell · 2026Article
- Article
- Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma.International journal of radiation oncology, biology, physics · 2026Review
- Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
19 authors.
Tyler E Miller *Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1269-1895
Chadi A El Farran *Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-9374-103X
Charles P Couturier *Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-8015-7160
Zeyu ChenDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Joshua P D'AntonioDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Julia VergaDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Martin A VillanuevaBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7630-1403
L Nicolas Gonzalez CastroBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-7699-5188
Yuzhou Evelyn TongBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-2652-5828
Tariq Al SaadiDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-9674-5175
Andrew N ChioccaDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Yuanyuan ZhangDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.
David S FischerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Dieter Henrik HeilandMicroenvironment and Immunology Research Laboratory, Medical Center - University of Freiburg, Freiburg, Germany.
Jennifer L GuerrieroLudwig Center at Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2104-5457
Kevin PetreccaDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-8140-6402
Mario L SuvaBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-9898-5351
Alex K ShalekBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-5670-8778
Bradley E BernsteinDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA. bradley_bernstein@dfci.harvard.edu.ORCID 0000-0002-5726-6278
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Kristin A Knouse · 1985 to 2026
$93.9MMOLECULAR IMMUNOLOGY AND TUMOR BIOLOGYT32CA009216 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 1985 to 2026
$10.6MQuantitative and functional characterization of therapeutic resistance in cancerU54CA217377 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LAUFFENBURGER, DOUGLAS A, MANALIS, SCOTT R · 2017 to 2021
$10.2MEpigenetic plasticity in tumor initiation and evolutionDP1CA216873 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BERNSTEIN, BRADLEY EVAN · 2016 to 2020
$5.9MImmunometabolic pathways enabled by PARP inhibition in breast cancerR37CA269499 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Jennifer L. Guerriero · 2022 to 2026
$2.3MTargeting myeloid cells to increase efficacy of immunotherapy against brain tumors.K08CA276819 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tyler Eugene Miller · 2023 to 2026
$846kInvestigating molecular mechanism of immune response during cancer progressionK00CA234842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, ZEYU · 2021 to 2024
$370kInvestigating molecular mechanism of T cell exhaustion in chronic infection and tumor microenvironmentF99CA234842 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHEN, ZEYU · 2018 to 2019
$78kNCI NIH HHS DP1 CA216873NCI NIH HHS F99 CA234842NCI NIH HHS K00 CA234842NCI NIH HHS K08 CA276819NCI NIH HHS P30 CA014051NCI NIH HHS R37 CA269499NCI NIH HHS T32 CA009216NCI NIH HHS U54 CA217377
Abstract
Gliomas are incurable malignancies notable for having an immunosuppressive microenvironment with abundant myeloid cells, the immunomodulatory phenotypes of which remain poorly defined
Indexed as
Brain NeoplasmsGliomaImmunomodulationMyeloid CellsAnimalsDexamethasoneFemaleGene Expression Regulation, NeoplasticHumansImmunotherapyInterleukin-1betaMaleMiceMicrogliaPhenotypeSingle-Cell AnalysisDexamethasoneInterleukin-1betaTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.